Zabopegdutide, a dual GLP-1/glucagon receptor agonist, produced significant reductions in liver fat, stiffness, and fibrosis biomarkers within 12 weeks in patients with metabolic dysfunction-associated fatty liver disease. These improvements occurred independently of weight loss, suggesting a direct hepatoprotective mechanism beyond metabolic reduction.
Key Points
- 75.8% achieved ≥30% liver fat reduction at 12 weeks
- Liver benefits persisted in patients with <5% weight loss
- Reductions in stiffness and fibrosis biomarkers preceded histology improvements
Longevity Analysis
Metabolic dysfunction-associated fatty liver disease represents a primary driver of age-related decline and mortality risk. This data demonstrates that targeted pharmacological intervention can interrupt hepatic fibrosis progression through dual metabolic and weight-independent pathways. The dissociation between liver improvement and weight loss suggests the compound engages direct hepatic signaling mechanisms—addressing inflammation and regenerative capacity at the tissue level rather than relying solely on systemic metabolic correction. This has implications for patients in whom weight loss alone proves insufficient to reverse liver pathology.
Original published by Longevity.Technology.